Compare Gold Fields Limited (GFI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs BIO-TECHNE Corp — how do they compare? Gold Fields Limited trades at $40.23 (market cap $36.72B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Gold Fields Limited is far larger — about 3.3× BIO-TECHNE Corp's market cap, and Gold Fields Limited pays the higher dividend (5.64%). Which is the better fit depends on your goals.
| GFI | TECH | |
|---|---|---|
Market Cap | $36.72B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $72.29 |
52-Week Low | $29.31 | $43.31 |
Enterprise Value | $38.16B | $11.32B |
Dividend Yield | 5.64% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $40.82, up 9.32% in 24 hours, reflecting strong momentum near recent highs. The stock shows a bullish technical signal with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Fundamentally, GFI exhibits robust profitability with a 40.76% net income margin and attractive valuation metrics, including a P/E of 10.36. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses, while 2025 revenue is projected to surge to $8.8B. Institutional interest is evident with Allspring Global increasing its stake by 62.3% in Q1 2026 (SEC filing, 2026-07-18).
The outlook for GFI is positive, driven by strong gold prices and operational growth, with a consensus price target of $52.00 offering ~27% upside. Risks include cost inflation, geopolitical factors affecting mining operations, and volatile cash flows from heavy investing activities. Analyst sentiment is cautiously optimistic with 44% buy ratings, but investors should monitor execution on earnings targets and debt levels, which rose to 25.01% of assets in 2024.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
